Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. decreased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 32.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 207,622 shares of the biopharmaceutical company's stock after selling 98,051 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.30% of Xencor worth $4,175,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Baillie Gifford & Co. increased its stake in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock worth $445,000 after buying an additional 744 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Xencor by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock valued at $587,000 after acquiring an additional 900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Xencor by 8.5% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company's stock worth $244,000 after acquiring an additional 949 shares during the last quarter. Diversified Trust Co lifted its stake in shares of Xencor by 7.8% in the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock worth $266,000 after acquiring an additional 1,017 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Xencor by 63.5% in the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 1,213 shares during the last quarter.

Insiders Place Their Bets

In other Xencor news, CEO Bassil I. Dahiyat sold 49,278 shares of the business's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the completion of the transaction, the chief executive officer now directly owns 352,615 shares of the company's stock, valued at $8,487,443.05. The trade was a 12.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares of the company's stock, valued at $4,698,441.92. This trade represents a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 136,050 shares of company stock valued at $3,277,609 over the last three months. Company insiders own 5.23% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on XNCR. Wedbush restated an "outperform" rating and set a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. Royal Bank of Canada upped their price target on shares of Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a report on Thursday, September 26th. Piper Sandler raised shares of Xencor from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $20.00 to $30.00 in a report on Monday, December 2nd. BMO Capital Markets reissued an "outperform" rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $36.50.

Xencor Stock Performance

XNCR traded up $0.02 on Friday, hitting $25.34. 413,590 shares of the company's stock were exchanged, compared to its average volume of 704,091. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $22.51 and a two-hundred day moving average of $20.64. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $27.24. The firm has a market cap of $1.77 billion, a PE ratio of -7.92 and a beta of 0.69.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million for the quarter, compared to analysts' expectations of $14.59 million. During the same period in the prior year, the firm earned ($0.40) EPS. The business's quarterly revenue was down 81.9% on a year-over-year basis. On average, research analysts anticipate that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.